Oncology company Turning Point seeking $100M IPO

Five months after raising an $80 million mezzanine round, cancer company Turning Point is aiming to reap $100 million in a NASDAQ listing

Read the full 235 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE